Arcturus Therapeutics Holdings Inc. - ARCT EV/Sales Multiple

Public company logo of arcturusrx.com (ARCT)

Arcturus Therapeutics (ARCT) combines an asset-light mRNA production model with a strong team of specialized scientists. The company's price-to-sales ratio reflects the business valuation trend, where 2618.58 represents the latest metric reading. However, global political tensions and sanctions seriously hinder the cross-border logistics of biosamples, creating risks for the development of innovative medicines.

Arcturus Therapeutics - ARCT Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

Arcturus Therapeutics Inc - analytical breakdowns and key metrics (ARCT)

Initial company analysis:Arcturus Therapeutics ARCT
Mass-produced product of Arcturus Therapeutics Holdings Inc.

The reliability of an equity asset is determined by comparing the business's market value with its operational efficiency. This indicator aggregates capitalization and net debt, dividing them by sales volume to eliminate the impact of leverage. For Arcturus Therapeutics (ARCT), such a valuation is critical due to its dependence on RNA component imports and the complexity of patent protection. By analyzing the enterprise value-to-annual revenue multiple, an investor identifies an overvaluation of the asset against a backdrop of geopolitical risks.